Security
SRPT · Sarepta Therapeutics, Inc.
SRPTNASDAQCommon stockCurrentCIK 873303Updated Sep 24, 2026
Name history
Sarepta Therapeutics, Inc. · through Sep 23, 2026AVI BIOPHARMA INC · through Jul 12, 2012ANTIVIRALS INC · through May 12, 1998
SRPT price & chart
Loading TradingView…
NASDAQ:SRPT on TradingView ↗About the company
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com or follow us on LinkedIn, X, Instagram and Facebook.
In the news
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion ↗
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT News provided by DJS Law Group LLP Aug 25, 2025, 03:11 ET Share this article Share to X Share this article Share to X LOS ANGELES , Aug. 25, 2025 /P ↗
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm News provided by The Schall Law Firm Aug 25, 2025, 03:10 ET Share this article Share to X Share this article Share to X LOS ANGELES , Aug. 25, 2025 /PRNewswire/ -- The Schall Law Firm ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 3,349,703,000Source | 3,963,173,000Source | 3,264,576,000Source | 3,128,366,000Source |
| Property, Plant and Equipment, NetUSD | 345,125,000Source | 340,336,000Source | 227,154,000Source | 180,037,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 801,282,000Source | 1,103,010,000Source | 428,430,000Source | 966,777,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 398,233,000Source | 601,988,000Source | 400,327,000Source | 214,628,000Source |
| Inventory, NetUSD | 914,744,000Source | 749,960,000Source | 322,859,000Source | 203,968,000Source |
| Assets, CurrentUSD | 2,537,938,000Source | 3,073,463,000Source | 2,579,331,000Source | 2,557,861,000Source |
| Operating Lease, Right-of-Use AssetUSD | 125,495,000Source | 148,310,000Source | 129,952,000Source | 64,954,000Source |
| Other Assets, NoncurrentUSD | 155,554,000Source | 79,915,000Source | 136,771,000Source | 317,936,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,209,081,000Source | 2,435,431,000Source | 2,405,239,000Source | 2,743,416,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 11,000Source | 10,000Source | 9,000Source | 9,000Source |
| Retained Earnings (Accumulated Deficit)USD | -4,876,984,000Source | -4,210,974,000Source | -4,446,213,000Source | -3,910,236,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 272,000Source | -218,000Source | 918,000Source | -1,664,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,140,622,000Source | 1,527,742,000Source | 859,337,000Source | 384,950,000Source |
| Additional Paid in Capital, Common StockUSD | 6,042,586,000Source | 5,738,924,000Source | 5,304,623,000Source | 4,296,841,000Source |
| Liabilities and EquityUSD | 3,349,703,000Source | 3,963,173,000Source | 3,264,576,000Source | 3,128,366,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 1,095,290,000Source | 731,684,000Source | 653,659,000Source | 619,604,000Source |
| Operating Lease, Liability, CurrentUSD | 11,196,000Source | 13,273,000Source | 17,845,000Source | 15,489,000Source |
| Accounts Payable, CurrentUSD | 280,841,000Source | 214,442,000Source | 164,918,000Source | 95,875,000Source |
| Operating Lease, Liability, NoncurrentUSD | 199,378,000Source | 192,473,000Source | 140,965,000Source | 57,578,000Source |
| Other Liabilities, NoncurrentUSD | 1,529,000Source | 1,750,000Source | 3,000,000Source | 42,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 359,659,000Source | 373,513,000Source | 314,997,000Source | 418,996,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 1,691,800,000Source | 2,008,400,000Source |
| Long-term DebtUSD | 828,974,000Source | 1,137,124,000Source | 1,237,998,000Source | 1,544,292,000Source |
| Long-term Debt, Current MaturitiesUSD | — | 0Source | 105,483,000Source | — |
| Short-term InvestmentsUSD | 138,368,000Source | 251,782,000Source | 1,247,820,000Source | 1,022,597,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -713,410,000Source | 235,239,000Source | -535,977,000Source | -703,488,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 44,521,000Source | 37,724,000Source | 44,397,000Source | 41,864,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 123,396,000Source | 184,300,000Source | 182,514,000Source | 233,018,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -203,755,000Source | 201,661,000Source | 185,699,000Source | 61,638,000Source |
| Increase (Decrease) in InventoriesUSD | 301,093,000Source | 395,170,000Source | 147,714,000Source | 50,780,000Source |
| Deferred Income Tax Expense (Benefit)USD | -363,000Source | -249,000Source | -165,000Source | -612,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -205,479,000Source | -205,787,000Source | -500,993,000Source | -325,346,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 69,641,000Source | 755,561,000Source | -165,803,000Source | -1,046,883,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 101,972,000Source | 136,956,000Source | 76,106,000Source | 30,824,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 25,013,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -168,344,000Source | 124,806,000Source | 125,004,000Source | 232,507,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -304,182,000Source | 674,580,000Source | -541,792,000Source | -1,139,722,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 814,407,000Source | 1,118,589,000Source | 444,009,000Source | 985,801,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 14,913,000Source | 15,856,000Source | 15,923,000Source | 44,418,000Source |
| Income Taxes Paid, NetUSD | 37,632,000Source | 22,587,000Source | 15,081,000Source | 1,695,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 14,300Source | — | 182,514,000Source | 233,018,000Source |
| Amortization of Debt Issuance CostsUSD | 12,100,000Source | 5,000,000Source | 5,200,000Source | 7,500,000Source |
| Amortization of Intangible AssetsUSD | 2,622,000Source | 2,405,000Source | 1,559,000Source | 714,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 1,691,800,000Source | 2,008,400,000Source |
| DepreciationUSD | 51,400,000Source | 42,700,000Source | 42,500,000Source | 40,000,000Source |
| Equity Method Investment, Other than Temporary ImpairmentUSD | 0Source | 0Source | 30,321,000Source | 2,575,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | 0Source | 0Source | 102,000,000Source | 0Source |
| Gain (Loss) on InvestmentsUSD | -15,914,000Source | — | — | — |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | — | -10,770,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | 16,862,000Source | 0Source | -387,329,000Source | -125,441,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 0Source | 0Source | — | — |
| Income Tax Expense (Benefit)USD | 11,185,000Source | 25,535,000Source | 15,879,000Source | 13,525,000Source |
| Inventory Write-downUSD | 165,300,000Source | — | — | — |
| Investment Income, InterestUSD | 30,763,000Source | 30,635,000Source | 36,257,000Source | 16,488,000Source |
| Net Income (Loss) Attributable to ParentUSD | -713,410,000Source | 235,239,000Source | -535,977,000Source | -703,488,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -713,410,000Source | — | — | — |
| Nonoperating Income (Expense)USD | -2,444,000Source | 42,693,000Source | -252,274,000Source | -153,762,000Source |
| Other Nonoperating Income (Expense)USD | -19,306,000Source | 42,693,000Source | 33,055,000Source | — |
| Proceeds from Issuance of Common StockUSD | 20,000,000Source | — | — | 0Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | 18,703,000Source | — | 51,246,000Source | 30,043,000Source |
| Restructuring CostsUSD | 134,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 1,864,296,000Source | 1,787,960,000Source | 1,144,876,000Source | 843,769,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 491,716,000Source | 557,872,000Source | 481,871,000Source | 451,421,000Source |
| Operating Income (Loss)USD | -699,781,000Source | 218,081,000Source | -267,824,000Source | -536,201,000Source |
| Other Nonoperating Income (Expense)USD | -19,306,000Source | 42,693,000Source | 33,055,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -702,225,000Source | 260,774,000Source | -520,098,000Source | -689,963,000Source |
| Income Tax Expense (Benefit)USD | 11,185,000Source | 25,535,000Source | 15,879,000Source | 13,525,000Source |
| Net Income (Loss) Attributable to ParentUSD | -713,410,000Source | 235,239,000Source | -535,977,000Source | -703,488,000Source |
| Earnings Per Share, BasicUSD per share | -7.13Source | 2.47Source | -5.8Source | -8.03Source |
| Earnings Per Share, DilutedUSD per share | -7.13Source | 2.34Source | -5.8Source | -8.03Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 100,120,000Source | 95,075,000Source | 92,398,000Source | 87,559,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 100,120,000Source | 107,875,000Source | 92,398,000Source | 87,559,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 2,622,000Source | 2,405,000Source | 1,559,000Source | 714,000Source |
| Costs and ExpensesUSD | 2,898,018,000Source | 1,683,898,000Source | 1,511,160,000Source | 1,469,214,000Source |
| Current Income Tax Expense (Benefit)USD | 11,548,000Source | 25,784,000Source | 16,044,000Source | 14,137,000Source |
| Gain (Loss) on InvestmentsUSD | -15,914,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -635,699,000Source | 168,666,000Source | -238,660,000Source | -251,384,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 0Source | 0Source | — | — |
| Interest ExpenseUSD | -38,140,000Source | -18,391,000Source | 22,010,000Source | 53,248,000Source |
| Interest Expense, DebtUSD | 34,800,000Source | 20,600,000Source | 22,000,000Source | 53,200,000Source |
| Investment Income, InterestUSD | 30,763,000Source | 30,635,000Source | 36,257,000Source | 16,488,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -713,410,000Source | — | — | — |
| Nonoperating Income (Expense)USD | -2,444,000Source | 42,693,000Source | -252,274,000Source | -153,762,000Source |
| Restructuring CostsUSD | 134,000Source | — | — | — |
Filing attachments
srpt-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 srpt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments - New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth - Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and $98.1 million of ELEVIDYS net pro…
Read attachment ↗d101719dex991.htm · 8-K · 2026-07-27
EX-99.1 4 d101719dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer Severino joins Sarepta’s Board of Directors Doug Ingram to retire from Sarepta CAMBRIDGE, Mass., July 27, 2026 - (BUSINESS WIRE) - Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severin…
Read attachment ↗srpt-ex99_1.htm · 8-K · 2026-05-06
EX-99.1 2 srpt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments - Net product revenues for the first quarter 2026 totaled $330.5 million, consisting of $102.0 million of ELEVIDYS net product revenue and $228.6 million of PMO net product revenues - Achieved GAAP and non-GAAP operating income of $358.4 million and $397.7 million for the first quarter 2026, respectively - siRNA pipeline delivers…
Read attachment ↗srpt-ex99_1.htm · 8-K · 2026-02-25
EX-99.1 2 srpt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments - Net product revenues for the full year 2025 totaled $1,864.3 million, consisting of $965.6 million of PMO net product revenue and $898.7 million of ELEVIDYS net product revenue - Net product revenues for the fourth quarter 2025 totaled $369.6 million, consisting of $259.2 million of PMO net product revenue and $110…
Read attachment ↗srpt-ex99_1.htm · 8-K · 2026-01-12
EX-99.1 2 srpt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues • Preliminary total net product revenue of $369.6 million for the fourth quarter and $1.86 billion for full-year 2025 • Preliminary ELEVIDYS net product revenue totaled $110.4 million for the fourth quarter and $898.7 million for full-year 2025 • Preliminary PMO net product revenues totaled $259.2 million for the fourth quarter and $965.6 million for…
Read attachment ↗d32354dex41.htm · 8-K · 2025-12-19
EX-4.1 2 d32354dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 SAREPTA THERAPEUTICS, INC., as Issuer AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of December 18, 2025 to the Indenture dated as of August 28, 2025 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Certain Terms Defined in the Base Indenture 1 …
Read attachment ↗